혈소판 풍부 혈장(PRP) 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of platelet rich plasma (PRP) Market

The global platelet rich plasma (PRP) market was valued at USD 513.7 million in 2025 and is projected to grow from USD 591.8 million in 2026 to USD 1,388.90 million by 2034, exhibiting a strong CAGR of 11.30% during the forecast period. North America dominated the global market with a 44.60% share in 2025, supported by strong healthcare infrastructure, FDA approvals, and high treatment adoption rates.

PRP therapy is a regenerative treatment that uses growth factors from a patient's own blood to accelerate tissue healing. It is widely applied in orthopedics, neurology, cosmetic procedures, and wound care. Rising cases of musculoskeletal disorders, sports injuries, and chronic diseases are significantly driving global market growth.

COVID-19 Impact

The COVID-19 pandemic negatively impacted the market in 2020 due to travel restrictions and reduced patient visits. According to an NIH survey (2020), about 60.9% of patients in Italy missed wound care appointments, reducing treatment volumes. However, recovery in hospital and ambulatory surgical center (ASC) visits helped the market return to pre-pandemic levels by 2022, stabilizing growth from 2023 onward.

Latest Trends

One of the major trends is the increasing use of PRP in cosmetic rejuvenation procedures, including wrinkle reduction, acne scar treatment, skin tightening, and complexion improvement. PRP is also gaining traction in dental applications, hair restoration, and chronic wound management. North America witnessed growth from USD 171.8 million in 2023 to USD 198.5 million in 2024, reflecting expanding treatment applications.

Market Growth Drivers

Rising Sports and Musculoskeletal Injuries

PRP therapy is increasingly used for treating ligament injuries, cartilage damage, tendon disorders, and sports-related trauma. According to Courier-Journal (2023), over 3.5 million sports injuries occur annually in the U.S., driving demand for regenerative therapies. Additionally, WHO reported that 528 million people were living with osteoarthritis in 2019, further supporting long-term adoption.

Expanding Use in Chronic Disorders

PRP applications now extend to arthritis, diabetes-related wounds, varicose veins, dental implants, and neurological conditions. The aging population, particularly individuals above 55 years (who account for 73% of osteoarthritis cases), is accelerating product demand globally.

Market Restraints

High treatment costs and limited reimbursement remain major challenges. A single PRP session costs between USD 500 and USD 2,500, and repeated treatments are often required. Limited insurance and Medicare reimbursement policies further restrict widespread adoption.

Segmentation Analysis

By Product

The market is segmented into Pure PRP, Leukocyte-Rich PRP (L-PRP), Platelet Rich Fibrin (PRF), and others.

• Pure PRP dominated with a 60.88% share in 2026, driven by reconstructive care applications and FDA approvals such as EmCyte's PureBMC system.
• L-PRP held 12.1% share in 2024.
• PRF is projected to grow steadily due to strong demand in oral surgery and dental applications.

By Application

• Wound care led with 34.49% share in 2026, driven by increasing workplace injuries and surgical wound management.
• Orthopedics held a significant share in 2024, supported by rising arthritis and ligament injuries.
• Cosmetics and neurology also captured suitable shares due to growing aesthetic procedures and nerve regeneration applications.

By End User

• Hospitals & ASCs dominated with 74.43% share in 2026, as patients prefer hospital-based treatment for chronic and acute wounds.
• Specialty clinics are projected to grow rapidly due to increasing cosmetic and hair restoration procedures.
• Home-use PRP kits are also contributing to market expansion.

Regional Insights

North America

North America generated USD 229.33 million in 2025 and USD 265.15 million in 2026, maintaining leadership due to FDA approvals and advanced healthcare systems. The U.S. market remains the primary contributor.

Europe

Europe holds a substantial share, supported by rising rheumatoid arthritis prevalence (0.8-1.2% in Germany in 2021). The UK and Germany markets continue expanding due to regulatory support and disease burden.

Asia Pacific

Asia Pacific is projected to record the highest CAGR during the forecast period. Growing awareness, increasing sports injuries, and expanding dental and cosmetic procedures are driving adoption.

Latin America & Middle East & Africa

These regions are experiencing steady growth due to rising healthcare investments and regulatory improvements to standardize platelet concentrate production.

Competitive Landscape

The market is fragmented with key players including:

• Arthrex, Inc.
• Zimmer Biomet
• Stryker Corporation
• EmCyte Corporation
• Terumo Corporation
• Exactech, Inc.
• Isto Biologics

Strategic initiatives such as acquisitions (Isto Biologics acquiring TheraCell in April 2022) and partnerships (Terumo's agreement with Osteopore in 2021) are strengthening market positions.

Conclusion

The global platelet rich plasma market is expected to grow significantly from USD 513.7 million in 2025 to USD 1,388.90 million by 2034, driven by rising orthopedic disorders, sports injuries, cosmetic procedures, and regenerative medicine advancements. Despite challenges such as high treatment costs and limited reimbursement, expanding applications and strategic industry developments are expected to sustain strong double-digit growth throughout the forecast period.

Segmentation

By Product

• Pure Platelet Rich Plasma (Pure PRP)
• Leukocyte-rich Platelet Rich Plasma (L-PRP)
• Platelet Rich Fibrin (PRF)
• Others

By Application

• Orthopedics
• Neurology
• Cosmetics
• Wound Care
• Others

By End User

• Hospitals & ASCs
• Specialty Clinics
• Others

By Region

• North America (By Product, By Application, By End User, and By Country)
  • U.S.
  • Canada
• Europe (By Product, By Application, By End User, and By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, By Application, By End User, and By Country/Sub-Region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, By Application, By End User, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, By Application, By End User, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Chronic Diseases, By Key Countries/Region, 2025
• 4.2. Key Industry Developments
• 4.3. Overview of Regulatory Scenario, By Key Regions
• 4.4. Advancements in Platelet Concentrates
• 4.5. Impact of Covid-19 on the Market

5. Global Platelet Rich Plasma Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Pure Platelet Rich Plasma (Pure PRP)
  • 5.1.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
  • 5.1.3. Platelet Rich Fibrin (PRF)
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Orthopedics
  • 5.2.2. Neurology
  • 5.2.3. Cosmetics
  • 5.2.4. Wound Care
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & ASCs
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Platelet Rich Plasma Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Pure Platelet Rich Plasma (Pure PRP)
  • 6.1.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
  • 6.1.3. Platelet Rich Fibrin (PRF)
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Orthopedics
  • 6.2.2. Neurology
  • 6.2.3. Cosmetics
  • 6.2.4. Wound Care
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & ASCs
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Platelet Rich Plasma Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Pure Platelet Rich Plasma (Pure PRP)
  • 7.1.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
  • 7.1.3. Platelet Rich Fibrin (PRF)
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Orthopedics
  • 7.2.2. Neurology
  • 7.2.3. Cosmetics
  • 7.2.4. Wound Care
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & ASCs
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Platelet Rich Plasma Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Pure Platelet Rich Plasma (Pure PRP)
  • 8.1.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
  • 8.1.3. Platelet Rich Fibrin (PRF)
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Orthopedics
  • 8.2.2. Neurology
  • 8.2.3. Cosmetics
  • 8.2.4. Wound Care
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & ASCs
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Platelet Rich Plasma Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Pure Platelet Rich Plasma (Pure PRP)
  • 9.1.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
  • 9.1.3. Platelet Rich Fibrin (PRF)
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Orthopedics
  • 9.2.2. Neurology
  • 9.2.3. Cosmetics
  • 9.2.4. Wound Care
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & ASCs
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Platelet Rich Plasma Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Pure Platelet Rich Plasma (Pure PRP)
  • 10.1.2. Leukocyte-rich Platelet Rich Plasma (L-PRP)
  • 10.1.3. Platelet Rich Fibrin (PRF)
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Orthopedics
  • 10.2.2. Neurology
  • 10.2.3. Cosmetics
  • 10.2.4. Wound Care
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals & ASCs
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Arthrex, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Isto Biologics
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Zimmer Biomet
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. ThermoGenesis Holdings, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Exactech, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. EmCyte Corporation
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Stryker
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Terumo Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. Johnson & Johnson Services, Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)